At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 31 enrolled
Drug / intervention
Posaconazole IV +2 moredrug
Likely dose
Posaconazole IV 6 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole (POS, MK-5592) in Pediatric Participants Aged 2 to Less Than 18 Years With Invasive Aspergillosis
In Brief
A Phase 2 clinical trial evaluating Posaconazole IV, Posaconazole PFS, and 1 other intervention for Invasive Aspergillosis. Completed, enrolled 31 participants across 29 sites in 10 countries.
Detailed Summary
This study will evaluate the safety, efficacy, and pharmacokinetics of posaconazole (POS) intravenous (IV) and oral formulations in pediatric participants 2 to \<18 years of age with invasive aspergillosis (IA).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInvasive Aspergillosis
CountriesBelgium, Greece, Hungary, Israel, Italy, Mexico, Peru, Russia, South Korea, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedJan 2020
Enrollment StartJul 2020
Primary CompletionDec 2023
TodayJul 2026
First PostedJan 6, 2020
Enrollment StartJul 2, 2020
Primary CompletionDec 18, 2023
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 6.5 years ago
Interventions
Posaconazole IVdrug
Posaconazole (POS) 6 mg/kg body weight by IV infusion
Posaconazole PFSdrug
Dosing based on weight-band taken orally
Posaconazole tabletdrug
POS tablet 300 mg taken orally